Re BioInfect Conference 2015

RNS Number : 1006F

Redx Pharma plc

10 November 2015

 

10 November 2015

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Group")

BioInfect Conference

Redx joins industry leaders to combat one of the biggest threats to global health

Redx, the drug discovery and development company, is pleased to be participating today at BioInfect, the major one day conference bringing together industry leaders to focus on the threat of antimicrobial resistance and the critical issues relating to the development of new anti-infectives.

Antimicrobial resistance ("AMR") is an increasingly serious global public health issue that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. Redx is working in collaboration with the NHS to tackle AMR, and the Group's anti-infective subsidiary has one of the biggest research teams in the UK, if not Europe, developing the next generation of antibiotics. AMR requires action across all government sectors and society, and the BioInfect Conference recognises this urgent need. 

Today's event in Alderley Park features a keynote address by Lord Jim O'Neill, who is leading the UK's Review on Antimicrobial Resistance. Dr Neil Murray, CEO of Redx, James Anderson, Head of Corporate Government Affairs, GSK, Ramanan Laxminarayan, VP for Research and Policy for the Public Health Foundation of India and Hala Audi, the Head of the AMR review team, will be speaking on the "proposed financial models to address the global AMR challenge".

The conference, now in its third year, is sponsored by Boyds, Shore Capital, HGF Limited, Manchester Science Partnerships and Acceleris Capital.

Dr Neil Murray, Chief Executive of Redx, commented:

"We are pleased to be taking part in BioInfect, a conference looking at the impact of antimicrobial resistance, which is one of the biggest problems facing world health today. BioInfect has an important role in helping to share knowledge and foster collaboration between companies, policymakers and health workers. Redx's anti-infective subsidiary is at the forefront of AMR research."

For further information, please contact:

Redx Pharma Plc		T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
KTZ Communications		T: 020 3178 6378
Katie Tzouliadis

About BioInfect

For more information please visit the conference website: http://www.bionow.co.uk/events/2015bioinfectconference.aspx

About Redx Pharma Plc

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

NRAFSFFWUFISESF